Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Diamyd study in newly diagnosed type 1 diabetes
NL-OMON33991Phase 3Active, not recruiting
- Sponsor
- Diamyd Medical
- Start
- Oct 2008
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Diamyd in diabetes mellitus type 1 (T1D) (3 arms), sponsored by Diamyd Medical. Primary endpoint: Change in stimulated C-peptide AUCmean 0-120 minutes during MMTT. Started Oct 2008; status: active, not recruiting.
02
Drugs
Diamyd
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on NL-OMON33991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33991.